Biotechnology, a strategic planning orphan: towards an effective strategy framework for biotechnology firms
Requires Subscription or Fee PDF

Keywords

Strategy
Five Forces Model
Biotechnology

Abstract

Drug development biotechnology firms are most appropriately conceptualized as intermediaries in the pharmaceutical R&D value chain. Because they generally do not launch products themselves, generate significant revenues or compete in traditional markets, the established strategic planning frameworks and tools, such as SWOT, PESTLE and Gap analysis, have little utility. Porter’s Five Forces Model (FFM) is a strategic planning framework that is prominent in texts, but has not been applied to biotechnology firms to any significant extent. This study reports on its application in one drug development biotechnology firm and concludes that, like the other techniques, FFM also fails for biotechnology firms. This is because it is rooted in traditional, highly-competitive markets, where profit maximization is the goal, and not the world of the R&D intermediary, where value creation is the measure of success. Despite the misfit of the FFM for biotechnology firms, the notion that strategy can be derived by consideration of the forces that influence success may provide the basis for a new strategy framework relevant to the business of biotechnology.
https://doi.org/10.5912/jcb748
Requires Subscription or Fee PDF

References

Pisano, G. (2006) Science business: The promise, the reality, and the future of biotech. Boston: Harvard Business School Press.

Scheer, O., O’Keefe, J. and Wintermantel, T. (2013) Unleashing pharma from the R&D value chain. A.T. Kearney report 2013. (https://www.atkearney.com/documents/10192/1641099/Unleashing+Pharma.pdf), accessed 25 June 2016.

DiMasi, J., Feldman, L., Seckler, A. and Wilson, A. (2010) Trends in risks associated with new drug development: Success rates for investigational drugs. Clinical Pharmacology & Therapeutics 87(3): 272-277.

McNamee, L. and Ledley, F. (2013) Translational science by public biotechnology companies in the IPO “class of 2000â€: The impact of technological maturity. PLoS One 8(12): 1-7.

Muller, C. (2002) Strategic management: A tool for growth in the biotechnology sector. Journal of Commercial Biotechnology 8(3): 226-234.

Wu, W., Couch, R., Suharto, Y. and Ahn, M. (2015) Reverse stock splits in the biotechnology industry: An effectuation approach. Journal of Commercial Biotechnology 21(1): 3-18.

Chavakula, V., Kim, S., Liu, D. and Marathe, R. (2007) Pfizer expanding into biopharmaceuticals. (http://www.mcafee.cc/Classes/BEM106/Papers/2007/Pfizer.pdf), accessed 25 June 2016.

Freund, M. and Niemann, E. (2009) Healthcare sector report. (http://amcp.org/WorkArea/DownloadAsset.aspx?id=13023), accessed 25 June 2016.

Kasapi, Z. and Mihiotis, A. (2011) Management as applied to new products penetration in the competitive environment of pharmaceutical industry. Interdisciplinary Journal of Research in Business 1(10): 73-85.

Porter, M. (2008) The five competitive forces that shape strategy. Harvard Business Review 86(1): 1-18.

Grundy, T. (2006) Rethinking and reinventing Michael Porter's five forces model. Strategic Change 15(5): 213-229.

Coyne, K. and Subramaniam, S. (1996) Bringing discipline to strategy. McKinsey Quarterly 4: 14-25.

Dobbs, M. (2014) Guidelines for applying Porter's five forces framework: A set of industry analysis templates. Competitiveness Review 24(1): 32-45.

Cha, J., Moyer, M. and Geller, D. (2013) Nektar Therapeutics strategy report. Bridges Consulting Group, (http://economics-files.pomona.edu/jlikens/SeniorSeminars/Likens2013/reports/nektar.pdf), accessed 25 June 2016

Shimasaki, C. (2014) Understanding biotechnology product sectors. In: Shimasaki, C. ed. Biotechnology Entrepreneurship. Academic Press: Boston, MA, 113-138.

Toth, G. (2013) The financial ecosystem available to early-stage biotechnology firms and its misalignment with interests of these firms, of the biotechnology industry and with global disease burden. Journal of Commercial Biotechnology 19(2): 17-26.

Houston, C., Graham J.E. and Schuhmann, P. (2012) Biotechnology valuation and governance: Drug development and board of directors composition. Journal of Commercial Biotechnology 19(1): 7-23.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.